Cell-Based Assays - Global Strategic Business Report

Global Industry Analysts, Inc, March 2012, Pages: 511

This report analyzes the worldwide markets for Cell-Based Assays in US$ Million by the following Product Segments: Assay Kits (Functional Assays, Cell Death-Associated Assays, & Cell Growth-Associated Assays), and Laboratory Automation. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 73 companies including many key and niche players such as BD Biosciences, Beckman Coulter, Inc., BioVision, Inc., Caliper Life Sciences, Inc., Cisbio Bioassays, DiscoveRx Corporation, EMD Millipore, Enzo Life Sciences, Inc., Evotec AG, GE Healthcare Life Sciences, Life Technologies Corp., New England Biolabs Inc., PerkinElmer, Inc., Promega Corporation, ProQinase GmbH, Qiagen NV, Sigma-Aldrich, StemCells, Inc., Thermo Fisher Scientific, Inc., and Xenometrix AG. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.

For information on site licence pricing please click on Enquire before buying.

CELL-BASED ASSAYS

A GLOBAL STRATEGIC BUSINESS REPORT

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-3
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
Assay Kits I-4
Functional Assays I-4
Cell Death-Associated Assays I-4
Cell Growth-Associated Assays I-4
Lab Automation I-4

II. Executive Summary

1. CELL-BASED ASSAYS: A PRIMER II-1

2. INDUSTRY OVERVIEW II-2
Cell-based Assays: A Prelude II-2
Cell-Based Assays Emerge as a Popular Tool in Drug Discovery
and Basic Research II-2
HTS and UHTS (High Throughput Screening and Ultrahigh-
throughput Screening Assays) II-3
Trends in Cell-Based Assay Market II-4
Growing Inclination Towards In-vitro Assays for Toxicology
Studies II-4
Industry Trends II-4
Cell-Based Assays: A Leading Drug Discovery Methodology II-4
Economy of Time and Cost Drives the Use of Cell-Based Assays
Over Other Techniques II-4
Growing Focus on the Development of Reproducible and Robust
Cell-based Assays II-5
HTS and Advancements in the Stem Cell Arena: A Growing Trend II-5
Increasing Use of Cell-Based Assays over Other Methods in
Toxicity Testing II-5
Functional Assays: An Effective Way of Predicting Specific
Toxic Effects II-6
Rising Interest in Cell-based Assays Propels the Development
of Improved Product Offerings II-6
Automation of Cell-based Assays: A Growing Trend II-6
Technological Advancements in Drug Discovery Processes Spurs
Cell-Based Assay Market II-6
Development of Label-free Cell-based Assays: A Recent Trend in
Biological Assays II-7
Role of Surface Chemistries II-7
Limitations II-7
Microfluidics Systems in Cell-based Assays II-8
Cell-Based Assays Likely to Gain from Microfluidic Devices II-8
Other Trends II-8

3. CELL-BASED ASSAYS: AN OVERVIEW II-10
What Drives Advances in Cell-based Assays? II-10
Cell Culture Fundamentals II-10
An Insight into Cell Biology II-11
Cell-based Assays: Basic Facts II-11
Defining Cell-based Assays II-12
Assays II-12
Biological Assays II-12
Quantification of Biological Activity II-12
Cell-based Assays II-13
Cell Based Assays: Prerequisites for Proof Of Concept II-14
List of Factors to be Considered in Cell-Based Assays II-14
Contamination with Mycoplasma: A Critical Factor II-15
Modes of Contamination II-15
Prevention II-15
Uses of Cell-Based Assays II-16
Challenges II-16
Transient Transfection Cells II-16
Limitations II-17
Cell-based Assays: Product Segmentation II-17
Assay Kits II-17
Cell Function-Associated Assays II-17
Cell Growth-Associated Assays II-18
Cell Death-Associated Assays II-19
Lab Automation II-21
MIACA II-22
Innovations in Cell-based Assays for Screening II-22
MultiScreen Filter Plates from Millipore II-23
MultiScreen Filter Plates from Millipore by Type of Assay II-23
The Road Ahead II-24

4. PRODUCT INTRODUCTIONS/INNOVATIONS II-25
ACEA, Roche, and Vivo to Co-develop Novel xCELLigence System
Assays II-25
GE Healthcare and Geron Launch First Human Cardiomyocyte Product II-25
Biomonitor Unveils Novel Products in iLite™ Product Line II-25
Biomoda Receives Patent for Assay Use and Formulation II-26
TGR BioSciences Expands No-Wash SureFire Cellular Kinase
Assay Portfolio II-26
Hamamatsu Launches FDSS/uCELL Imaging Plate Reader II-26
Nexcelom Bioscience Launches Cellometer® Auto X4 II-27
SRU Biosystems Advances Label-free BIND Biosensors Range II-27
BioTek Instruments Introduces ELx405TM Microplate Bead Washer II-28
Platypus Technologies Purchases Oris™ Pro Cell Migration Assay II-28
Millipore Unveils MILLIPLEX® MAP EpiQuantTM Assay Panels II-28
Corning Launches Osteo-Assay Surface for Bone Cell Assays II-29
VisEn Medical Introduces Cat B 750 FAST Imaging Agent II-29
Roche Launches xCELLigence System and FuGENE HD II-29
Cisbio Bioassays Introduces Cellulerk II-30
AnaSpec Launches Calcein Acetoxymethyl Ester II-30
Patheon Launches Cell-based Assay Services II-30
Sigma-Aldrich Launches Precisio (TM) Kinases II-30
CXR Biosciences and Millipore Launch ToxReporter™ II-30
Beckman Coulter Launches Gallios Flow Cytometer II-31

5. PRODUCT INTRODUCTIONS/INNOVATIONS - A HISTORIC PERSPECTIVE BUILDER II-32
Cisbio Bioassays Introduces HTRF® Terbium Platform for GPCR
Screening II-32
Corning Launches Integrated LHA for the Epic® System II-32
PerkinElmer Unveils New AlphaScreen® SureFire® Assays II-32
Millipore Introduces High Content Kits for Neurotoxicity II-33
MaxCyte to Unveil MaxCyte STX Scalable Transfection System II-33
LSG and Gentronix to Launch Human Cell-Based Assays for
Genotoxicity in Japan II-33
Innovatis Introduces Cellavista II-34
Roche Applied Science Introduces xCELLigence System II-34
Bravo Introduces Liquid Handling Platform II-34
Cellix Introduces VenaFlux Platform II-34
MaxCyte Unveils ITF Inline Transfection System II-35
Thermo Fisher Scientific Expands Thermo Scientific Stem
CELLExcellence Program II-35
Tecan Group to Introduce New Infinite M1000 Multimode
Microplate Reader II-35
Beckman Coulter Integrates Quanta SC MPL with Cell Culture System II-35
Genetix Launches CellReporter Cell-Based Assay Platform II-36
Greiner Bio-One Unveils CELLSTAR® Plates II-36
PBL InterferonSource Introduces Gene Reporter Cell-Based Assay
Kit II-36

6. RECENT INDUSTRY ACTIVITY II-37
Merck Acquires Millipore, Forms New EMD Millipore Division II-37
DiscoveRx Acquires KINOMEscan™ Division from Ambit II-37
Asterand Takes over BioSeek II-37
LGC Standards Inks Partnership Agreement with Gentronix II-38
Cellular Dynamics International Partners with Promega II-38
CCS Cell Culture Service Acquires MaxCyte® STXTM Scalable
Transfection System II-39
Gentronix Inks Three-Year Agreement with GlaxoSmithKline II-39
DiscoveRx Enters into Co-Marketing Agreement with Jubilant II-40
Qiagen Takes Over SABiosciences II-40
Galapagos Signs Agreement with Dart Neuroscience II-40
Asterand Extends Collaboration with Bristol-Myers Squibb II-40
Pfizer Extends JAK3 Research Collaboration with Ligand
Pharmaceuticals II-41
StemCells to Expand Cell-Based Assay Platforms II-41
Caliper Life Sciences to Utilize Label-Free Bind Technology of
SRU Biosystems II-41
O2h Enters into First Biology Affiliate Partnership with Hypoxium II-42
Evotec and DiscoveRx Ink Agreement to Support HTS Services II-42
Millipore Takes Over Guava Technologies II-42
Beckman Coulter and Propel Labs Collaborate for Flow Cytometry II-42
Beckman Coulter Interfaces CyAn™ Flow Cytometer with
IntelliCyt's HyperCyt® II-43
XenoBiotic to Establish New Laboratory in China II-43
StemCells Acquires Stem Cell Sciences II-44
PerkinElmer Enters into Collaboration with Sangmyung University II-44
Seahorse Bioscience Takes Over BioProcessors II-45
Roche Inks Co-development and Marketing Agreement with
Axiogenesis II-45
ChanTest Takes over Applied Cell Sciences II-45

7. STRATEGIC CORPORATE DEVELOPMENTS - A HISTORIC PERSPECTIVE BUILDER II-46
Applied Biosystems and Invitrogen Merge to form Life
Technologies Corp. II-46
IBA Acquires Majority Stake in CISBIO II-46
Emory University Acquires Corning® Epic® System II-46
Biomonitor Takes Over Neutekbio II-47
Affymetrix to Take Over Panomics II-47
BioForce to Ink Agreement with University Pierre & Marie Curie
and Centre National de Recherché Scientifique II-48
Gentronix Inks Agreement with LSG II-48
Veridex Acquires Immunicon II-48
Caliper Life Sciences Partners with DiscoveRx II-48
BioSeek Inks Agreement with Dainippon Sumitomo Pharma II-49
3M Takes Over Acolyte Biomedica II-49
Invitrogen Corporation Acquires BioSource II-49
Caliper Life Sciences Acquires NovaScreen Biosciences II-50

8. FOCUS ON SELECT GLOBAL PLAYERS II-51
BD Biosciences (US) II-51
Beckman Coulter, Inc. (US) II-51
BioVision, Inc. (US) II-52
Caliper Life Sciences, Inc. (US) II-52
Cisbio Bioassays (US) II-53
DiscoveRx Corporation (US) II-53
EMD Millipore (US) II-53
Enzo Life Sciences, Inc. (US) II-54
Evotec AG (Germany) II-54
GE Healthcare Life Sciences (UK) II-55
Life Technologies Corp. (US) II-55
New England Biolabs Inc. (USA) II-56
PerkinElmer, Inc. (US) II-57
Promega Corporation (US) II-57
ProQinase GmbH (Germany) II-58
Qiagen NV (The Netherlands) II-58
Sigma-Aldrich (USA) II-59
StemCells, Inc. (US) II-59
Thermo Fisher Scientific, Inc. (US) II-59
Xenometrix AG (Switzerland) II-60

9. GLOBAL MARKET PERSPECTIVE II-61
Table 1: World Recent Past, Current and Future Analysis for
Cell-Based Assays by Geographic Region - US, Japan, Europe,
and Rest of World Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) II-61

Table 2: World Historic Review for Cell-Based Assays by
Geographic Region - US, Japan, Europe, and Rest of World
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) II-62

Table 3: World 15-Year Perspective for Cell-Based Assays by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Japan, Europe, and Rest of World Markets for Years 2003,
2011 and 2017 (includes corresponding Graph/Chart) II-63

III. MARKET

1. THE UNITED STATES III-1
A.Market Analysis III-1
Functional Assays - The Fastest Growing Product Segment III-1
Cell-Based Assay Market to Witness Significant Growth III-1
Life Science Remains the Largest End-Use Sector III-2
Market Trends III-2
Consolidation Rife in the Industry III-2
Select Acquisitions in the Industry (2006-2010) III-2
Increased Usage Drives Growth of Cell-based Assays III-3
Automation, High-Throughput Screening Pulls Down CBA Market
Growth, to a Certain Extent III-3
Custom Designed Assays to Drive the US Cell-based Assay Market III-3
Competitive Scenario III-4
US Functional Cell Assays Market III-4
Table 4: Leading Players in the US Functional Cell-Based
Assays Market (2009): Percentage Breakdown of Revenues for
Millipore, Promega, New England Biolabs, Sigma-Aldrich, BD
Biosciences and Others (includes corresponding
Graph/Chart) III-5

Table 5: Leading Players in the US Cell-Based Assays
Market (2009): Percentage Breakdown of Revenues for
Millipore, Promega, EMD Biosciences, BD Biosciences, New
England Biolabs and Others (includes corresponding
Graph/Chart) III-5

Table 6: Leading Players in the US Cell Growth-Based
Assays Market (2009): Percentage Breakdown of Revenues for
Promega, Life Technologies (Invitrogen), EMD Biosciences,
Millipore, BD Biosciences and Others (includes
corresponding Graph/Chart) III-6

Table 7: Leading Players in the US Cell Death-Based Assays
Market (2009): Percentage Breakdown of Revenues for EMD
Biosciences, Millipore, BD Biosciences, Life Technologies
(Invitrogen), Promega and Others (includes corresponding
Graph/Chart) III-6
Product Launches III-6
Strategic Corporate Developments III-15
Focus on Select Players III-20
B.Market Analytics III-27
Table 8: The US Recent Past, Current and Future Analysis
for Cell-Based Assays by Type - Assay Kits (Functional
Assays, Cell Death-Associated Assays, Cell Growth-Associated
Assays) and Laboratory Automation Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2009
through 2017 (includes corresponding Graph/Chart) III-27

Table 9: The US Historic Review for Cell-Based Assays by
Type - Assay Kits (Functional Assays, Cell Death-Associated
Assays, Cell Growth-Associated Assays) and Laboratory
Automation Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) III-28

Table 10: The US 15-Year Perspective for Cell-Based Assays
by Type - Percentage Breakdown of Dollar Sales for Assay
Kits (Functional Assays, Cell Death- Associated Assays, Cell
Growth-Associated Assays) and Laboratory Automation for
Years 2003, 2011 and 2017 (includes corresponding
Graph/Chart) III-29

2. JAPAN III-30
A.Market Analysis III-30
Strategic Corporate Developments III-30
B.Market Analytics III-31
Table 11: Japanese Recent Past, Current and Future Analysis
for Cell-Based Assays Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) III-31

Table 12: Japanese Historic Review for Cell-Based Assays
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) III-32

3. EUROPE III-33
A.Market Analysis III-33
Table 13: European Cell-Based Assay Market by End-Use
Sector (2011): Percentage Breakdown of Revenues for
Pharmaceuticals, Biotech Companies and Research/ Academia
(includes corresponding Graph/Chart) III-33
Market Outlook III-33
Cell-Based Assays Continue to Gain Impetus III-33
GPCR Targets to Drive Growth in Functional Cell Assay Market III-33
Growth in Cell Growth-Based Assay Kits Trails Behind Other
Segments III-34
Drive Towards Improved Efficiency in Development Programs
Provides Impetus to Cell Death Based Assays III-34
Market Trends III-35
Rising Number of Drug Targets Surge Demand for Cell-Based
Assays III-35
Laboratory Automation Drives the Growth of European CBA Market III-35
Cell-based Assays Represent the Primary Drug Discovery Tool
in HTS Laboratories III-35
Advancements in Technology, Identification Methods, and Lab
Disciplines in the CBA Market III-35
Cell-Based Assays: Regulatory Requirements III-36
Validation Assays for Compliance with ICH Guidelines III-36
Outsourcing of Validation Studies to CTOs III-36
Important Considerations for Outsourcing Validation Assays
to CTOs III-36
Competitive Landscape III-37
Product Launches III-37
Strategic Corporate Developments III-39
Focus on Select Players III-44
B.Market Analytics III-46
Table 14: European Recent Past, Current and Future Analysis
for Cell-Based Assays by Type - Assay Kits (Functional
Assays, Cell Death-Associated Assays, Cell Growth-Associated
Assays) and Laboratory Automation Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2009
through 2017 (includes corresponding Graph/Chart) III-46

Table 15: European Historic Review for Cell-Based Assays by
Type - Assay Kits (Functional Assays, Cell Death-Associated
Assays, Cell Growth-Associated Assays) and Laboratory
Automation Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) III-47

Table 16: European 15-Year Perspective for Cell-Based Assays
by Type - Percentage Breakdown of Dollar Sales for Assay
Kits (Functional Assays, Cell Death- Associated Assays, Cell
Growth-Associated Assays) and Laboratory Automation for
Years 2003, 2011 and 2017 (includes corresponding
Graph/Chart) III-48

4. REST OF WORLD III-49
A.Market Analysis III-49
Product Launch III-49
Strategic Corporate Developments III-49
B.Market Analytics III-51
Table 17: Rest of World Recent Past, Current and Future
Analysis for Cell-Based Assays Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2009 through
2017 (includes corresponding Graph/Chart) III-51

Table 18: Rest of World Historic Review for Cell-Based
Assays Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) III-52

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 73 (including Divisions/Subsidiaries - 79)

------------------------------------------
Region/Country Players
------------------------------------------
The United States 60
Europe 18
France 1
Germany 5
The United Kingdom 5
Rest of Europe 7
Asia-Pacific (Excluding Japan) 1
------------------------------------------

The demand for cell-based assays is largely being fuelled by the drug discovery industry. A notable trend is the use of cell-based assays in every phase of the drug discovery process, specifically High Throughput Screening (HTS), which witnessed substantial growth during the past few years. Cell-based assays currently represent an important segment of the drug discovery industry, with nearly 50% of all the assays focused on primary high throughput screening, and about 55% concentrated on selectivity screens. Characterized by versatility, cell-based assays represent a powerful research tool that facilitates in providing valuable information to the research and development community. Cell-based assays facilitate in studying the biological implication of various compounds, such as drugs, on cells as well as cellular systems. Cell-based assays could be further utilized in monitoring the biological implications of changes in the external environment, such as activation of cell receptor, stress, external stimuli, and alteration of gene activity and expression of proteins. Cell-based assays are emerging as the preferred tool for screening potential drug compounds as they facilitate in gaining access to a number of therapeutic targets. Further, cell-based assays also facilitate the study of toxic effects and metabolism in the early stages of drug discovery, thereby reducing the overall costs. The market is driven by advanced technological innovations as well as high throughput screening (HTS) systems.

Over the years, automation, the use of microfluidics systems, an increasing use in toxicity testing, and the development of label-free cell-based assays are some of the notable trends in the market for cell-based assays. Important growth drivers include new and enhanced screening technologies, automation, and non-invasive monitoring of cell-based assays. Cell-based assays are expected to continue to be a commercial success owing to its growing demand by drug development companies for the expansion of their drug portfolios. Although competitive technologies that provide similar analyses are expected to impinge on the market growth, the value provided by cell-based assays would possibly not be replaceable by a single methodology. Moreover, high-throughput processing of samples is likely to drive down per sample costs, facilitating the market to achieve economies of scale. However, certain market challenges do exist, which include costs, reagent stability, statistics, and robustness.

Regionally, the US and Europe are the major markets worldwide, as stated by the new market research report on Cell-based Assays. In the US, functional cell assays continued its dominance in the market as the largest segment in terms of revenues, driven by factors such as relative newness in the market and increasing adoption. Going forwards, the segment is expected to witness its share increasing with the growing demand for the analysis of functional events. Meanwhile, the cell death-based assays too are projected to witness substantial growth, driven by associated technical aspects of these assays that demand relatively higher cost for each experiment when compared to cell growth-based assays. Growth-wise, developed markets, including Europe and the US, are forecast to exhibit the fastest growth, with Europe expected to grow at a compounded annual growth rate of 11.82% during the analysis period.

Use of in-vitro test methods in toxicity testing is anticipated to take over in-vivo as well as animal model testing methods in the coming years. Cell-based assays are expected to emerge as a vital technology in serving this purpose, given their role either as a part of a tiered testing scheme or as test batteries in predicting human toxicity endpoints. However, the use of cell-based assays in toxicity testing is a time consuming process with a number of regulatory hurdles. Thus far, only a few stand-alone cell-based assays have been approved for completely replacing assays based on animal models, while some others have been validated for use as a part of a tiered testing scheme or as screening assays. Functional Cell Assays facilitate in gaining a better understanding of the mechanisms associated with the expression of toxic effects in humans and animals by analyzing specific functional responses. High Throughput/High Content (HTS/HCS) cell-based assays enable the evaluation of several toxicity endpoints, which is expected to enable the identification of various aspects associated with the onset of cell stress. This, in turn, aids in predicting specific cytotoxic effects.

Major players profiled in the report include BD Biosciences, Beckman Coulter Inc., BioVision Inc., Caliper Life Sciences Inc., Cisbio Bioassays, DiscoveRx Corp., GE Healthcare Life Sciences, Life Technologies, EMD Millipore, PerkinElmer Inc., Promega Corporation, ProQinase GmbH, Thermo Fisher Scientific Inc., Sigma-Aldrich, Xenometrix AG, among others.

Global Industry Analysts ©

- BD Biosciences
- Beckman Coulter
- BioVision
- Caliper Life Sciences
- Cisbio Bioassays
- DiscoveRx Corporation
- EMD Millipore
- Enzo Life Sciences
- Evotec AG
- GE Healthcare Life Sciences
- Life Technologies Corp.
- New England Biolabs Inc.
- PerkinElmer
- Promega Corporation
- ProQinase GmbH
- Qiagen NV
- Sigma-Aldrich
- StemCells
- Thermo Fisher Scientific
- Xenometrix AG

Customers who bought this item also bought

• Proteomics - Global Strategic Business Report
• Gene Amplification Technologies - Global Strategic Business Report
• Probiotics - Global Strategic Business Report
• Stem Cell Research - Global Business Strategic Report
• RNA Interference (RNAi) - Global Strategic Business Report
• Immunoassay Systems - Global Business Strategic Report
• Biotechnology Instrumentation - Global Strategic Business Report
• Biotechnology Reagents - Global Strategic Business Report
• Food Safety Testing - Global Strategic Business Report
• Genetic Testing - Global Strategic Business Report